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The bidirectional interaction of the gut microbiome and the innate immune 
system: implications for chemotherapy-induced gastrointestinal toxicity 
 
Abstract 
Chemotherapy-induced gastrointestinal toxicity (CIGT) occurs in up to 80% of all 
patients undergoing cancer treatment, and leads to symptoms such as diarrhoea, 
abdominal bleeding and pain. There is currently limited understanding of how to 
predict an individual patient’s risk of CIGT. It is believed the gut microbiome and its 
interactions with the host’s innate immune system plays a key role in the 
development of this toxicity and potentially other toxicities, however comprehensive 
bioinformatics modelling has not been rigorously performed. 
The innate immune system is strongly influenced by the microbial environment and 
vice-versa. Ways this may occur include the immune system controlling composition 
and compartmentalisation of the microbiome, the microbiome affecting development 
of antigen-presenting cells, and finally, the NLRP6 inflammasome orchestrating the 
colonic host-microbiome interface. This evidence calls into question the role of pre-
treatment risk factors in the development of gastrointestinal toxicity following 
chemotherapy.  
This review aims to examine evidence of a bidirectional interaction between the gut 
microbiome and innate immunity, and how these interactions occur in CIGT. In the 
future, knowledge of these interactions may lead to improved personalised cancer 
medicine, predictive risk stratification methods and the development of targeted 








Gastrointestinal toxicity is a significant and often dose-limiting adverse event of many 
chemotherapeutic agents used in cancer treatment, and is currently without a widely 
effective preventative or treatment strategy. Chemotherapy-induced gastrointestinal 
toxicity (CIGT) covers a constellation of cancer treatment-related adverse events 
often referred to as mucositis, as inflammation of the mucosa is a key aspect of 
tissue injury [1]. Characterised by painful ulcerative lesions along the entire 
gastrointestinal tract from mouth to anus, CIGT affects up to 80% of patients, 
depending on treatment regimen [1]. This leads to a heightened risk of adverse 
events such as infection and diarrhoea [2]. Symptoms such as abdominal bleeding 
and abdominal pain are common, and result in increased hospital stays and the 
need for parenteral nutrition [1]. These interventions, as well as use of pain 
management medication, results in a significantly increased economic cost, with 
Medicare data from Australia suggesting a cost of $1500 per episode of severe 
diarrhoea [3]. Available economic evidence substantially underestimates the larger 
societal burden and loss of quality of life of CIGT, caused by loss of productivity, 
need for informal care arrangements and increases in anxiety and depression levels 
[4]. Severe complications of CIGT such as bacteraemia and sepsis cause 
chemotherapy dose reductions and in profound cases, treatment cessation, 
compromising remission and increasing mortality [5]. Subsequently, CIGT presents 
as a major clinical and economic burden [2].  
Activation of transcription factors and upregulation and release of pro-inflammatory 
cytokines, in response to initiating events, are integral in the pathobiology of CIGT. 
More recent reports have focussed on an altered gut microbiome and damaged 
epithelial cells that produce cellular damage signals, causing activation of the innate 
immune system [6, 7]. These types of damage signals are recognised by receptors 
in the innate immune system, present on gastrointestinal tract cells [8]. 
It is now known that cancer treatments cause a raft of changes to the microbiome 
and host innate immune system [9]. There is significant heterogeneity in the 
microbiome and in immune function, and as such, this emergent data represents a 
chance to personalise cancer treatment, and allow the identification of patients at 
risk of severe symptoms [10, 11]. However there is a clear gap in knowledge in 
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translating these results from studies in radiotherapy- and immunotherapy-based 
patients into those with chemotherapy. The symptoms of CIGT and other cancer-
treatment induced toxicities (including radiotherapy) are similar, and while occur from 
different initiating events, have a similar timeline of pathogenesis [12]. These 
radiotherapy studies are beyond the scope of this review, however chemotherapy 
and radiotherapy are often concurrently used and these studies have been included 
in this review, in order to best assess available evidence. In addition to translating 
results into chemotherapy studies, it is not yet known if there is a specific gut 
microbiome profile that establishes risk of acute CIGT, and the role of the host 
immune system in maintaining or changing that profile. This review will provide 
evidence for an updated mechanistic hypothesis of CIGT wherein the bidirectional 
interaction of the host innate immune system and native microbiome may predict the 
severity of gastrointestinal toxicity a patient will suffer following chemotherapy. A 
semi-structured search of PubMed for full-text articles in English found more than 
1000 studies investigating the microbiome and/or innate immune system in 
chemotherapy-induced gastrointestinal toxicity. Search terms included: ‘microbiome’, 
‘chemotherapy-induced gastrointestinal toxicity’, ‘chemotherapy-induced mucositis’, 
‘cancer treatment diarrhoea’ and ‘chemotherapy microbiome’. Findings of key 
studies are summarised in tables 1-3.  
Pathobiology of CIGT 
Although CIGT is a significant concern in the treatment of cancer, the underlying 
mechanisms remain unclear. Sonis introduced a model in 2004, consisting of five 
continuous and overlapping phases. This model elegantly showed the integral role of 
transcription factor activation and subsequent upregulation and release of pro-
inflammatory cytokines, in response to initiating events [12]. These initiating events 
may be the innate immune system’s recognition of a Pathogen-Associated Molecular 
Pattern (PAMP) (e.g. lipopolysaccharide (LPS)), Damage-Associated Molecular 
Pattern (DAMP) (e.g. high mobility group box chromosomal protein 1, heat shock 
proteins) or ChemoRadiotherapy-Associated Molecular Pattern (CRAMP) [13]. There 
are several cellular mediators critical in these developmental events. These include 
nuclear factor kappa B (NF-κB), which causes the upregulation of up to 200 genes 
possibly involved in CIGT development [12]. Pro-inflammatory cytokines (primarily 
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tumour necrosis factor alpha (TNF-α), interleukin (IL)-1β, IL-6, IL-18 and IL-33 [14-
16]) are significantly elevated, leading to an amplification of apoptosis and epithelial 
damage [12].  
Since this model was introduced, more recent research suggests that the large 
population of bacteria resident in the small and large intestines plays a fundamental 
role in CIGT development (Figure 1). With recent advances in ‘omics’ technology, 
our ability to understand the unique idiosyncrasies of the microbiome is vastly 
improving. This onslaught of information highlights the need for improved 
translational integration of the role of gut bacteria in the pathobiological model.  
The gut microbiome 
The gut microbiome, defined here as the collection of bacteria and other 
microorganisms present in and around tissues from the mouth through to the anus, 
is made up of almost one hundred trillion microorganisms [17]. Functions include 
protective and immunological actions, supporting energy metabolism and triggering 
mucous barrier formation [8, 18]. The importance of the microbiome in normal 
development and functioning can be observed in germ-free mice, which are 
completely devoid of a microbiome raised under special conditions so they have no 
bacterial population. As a consequence of this, they have a variety of developmental 
differences including immature immune systems and altered digestive enzyme 
development, and are thus extremely susceptible to infection [19].  
Although the composition of the human gut microbiome is dependent on many 
factors such as diet, sex and ethnicity, much of its composition is determined in birth 
and infancy [19]. New findings also suggest that microbiome composition is not 
significantly associated with genetics, and is often more associated with environment 
[20]. While each individual’s gut microbiome is unique; the overall framework is often 
similar with the Firmicutes and Bacteroidetes phyla comprising over 90% of the gut 
microbiome [21]. Most bacteria belong to the Clostridium and Bacteroides genera, 
with major commensal (species which cohabitate with mutual benefit) species being 
Lactobacillus spp. and Bifidobacterium spp. [18]. Additionally, there are marked 
differences between the oral, gastric, small and large intestinal bacterial populations 
[22], reflecting physiological differences such as oxygen gradient, pH and presence 
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of antimicrobial peptides. The oral microbiome is dominated by Streptococcus spp., 
the small intestine by Lactobacillaceae and Enterbacteriaceae, and the colon by 
species such as Bacteriodaceae and Prevotellaceae [22, 23].  
The gastrointestinal epithelium is constantly in contact with adherent bacteria. A 
sensitive balance exists, with continual cross talk between the microbiome, immune 
cells and the mucosal barrier to maintain homeostasis [24]. A disruption in this 
balance, known as dysbiosis, has been shown to have a role in multiple autoimmune 
diseases such as multiple sclerosis [25]. Additionally, the inter-individual differences 
in the gut microbiome are now considered to be one of the key contributors to 
immune response in humans. This is thought to be via influence of an individual’s 
cytokine response (with strongest effects on interferon gamma (IFN-ɣ) and TNF-α 
production), and therefore disease susceptibility and overall immune function [26].  
The innate immune system 
The innate immune system is the first line of response to bacterial invasion or an 
aseptic tissue injury. It responds to danger signals by recruiting immune cells to the 
injury site, inducing inflammation and activating the adaptive immune system. The 
innate immune system is vital in the gastrointestinal tract, with the luminal 
gastrointestinal surface of being one of the largest common surface areas between 
host and environment. With a diverse range of microbes living so close to the host, 
the innate immune system is critical in maintaining immune tolerance to commensal 
microbes, whilst ensuring the rapid initiation of an immune response following 
invading pathogens.  
The innate immune system utilises many systems in the gastrointestinal tract in 
order to maintain homeostasis, including separation mechanisms including epithelial 
and mucosal layers, and compounds such as antimicrobial peptides and antibodies. 
Additionally, the innate immune system utilises a system of pattern recognition 
receptors that recognise microbial molecular patterns.  
One type of pattern recognition receptor, Toll-Like Receptors (TLRs), are particularly 
important in sensing molecular patterns from gut microbes. TLRs are highly 
conserved transmembrane receptors and are members of the Toll-Interleukin 1 
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Receptor signalling pathway [27]. TLRs are present in the gastrointestinal mucosa 
on basolateral and apical surfaces of epithelial cells, professional immune cells, 
enteric neurons and glia [28, 29]. There are eleven TLRs found in humans, 
recognising diverse ligands including RNA, DNA and LPS [27]. TLR4 is a particular 
focus of recent research due to its known expression changes following 
chemotherapy, and its ability to recognise patterns released by chemotherapy-
damaged cells and therefore will be the focus here [6]. TLR4 can be activated by 
exogenous and endogenous danger signals such as LPS, high mobility group box 
chromosomal protein 1 and heat shock proteins [27], causing a downstream 
signalling pathway of transcription factor (e.g. NF-κB) upregulation and pro-
inflammatory cytokine release.  
The role of TLR4 in CIGT development is now well known, with TLR4 knockout mice 
having less diarrhoea, weight loss and histological damage in response to irinotecan 
treatment [6]. However, there is some disparity surrounding the role of TLR4. One 
study where TLR4 was blocked using naloxone was unable to reduce irinotecan-
induced gastrointestinal damage [30], whereas other research has shown that TLR4 
agonist LPS can protect intestinal crypts from other insults such as radiation [31]. 
Studies have shown protection and exacerbation, possibly due to differences 
between acute and chronic injury [32] or chemotherapeutic agents, and therefore the 
role of TLR4 appears to be complicated and context-specific. Immunologic cell 
death, a form of cell death where dendritic cell activation leads to a specific T cell 
response, is caused by some anti-cancer agents such as oxaliplatin and is 
characterised by release of DAMPs. As TLR4 is of vital importance in binding 
DAMPs, it is possible that immunogenic cell death may contribute to modulating the 
role of TLR4 in CIGT.  
A bidirectional interaction: innate immunity and the gut microbiome 
The innate immune system is strongly influenced by the microbial environment [26]. 
However, there is growing evidence that the reverse is also true, and that the 
microbial environment is similarly influenced by the innate immune system [8, 33]. 
This bidirectional interaction between microbiome and immune system has been 
described by Hooper et al. [34] as ‘inside-out’ and ‘outside-in’ interactions, and is 
observed in a number of ways.  
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The immune system controls composition and compartmentalisation of the 
microbiome [34]. There is ample evidence to suggest that the host immune system is 
integral in selecting mucosal and luminal bacterial populations, ensuring there is 
minimal direct contact between the gastrointestinal surface and bacteria, keeping 
penetrant bacteria constrained to the lumen [8, 21]. Van den Abbeele et al. [21] 
hypothesised that a distinct mucosal-associated microbial community has many 
immune-regulating effects with large potential biological outcome. Conversely, 
bacteria likely to be targeted by host defences are restricted to the lumen. This paper 
also suggested an outer colonic mucus layer, situated between the inner mucus 
layer and the lumen, may contain a ‘backup’ of microorganisms, which could act as 
an inoculum to restore the initial microbial balance after a perturbation, ensuring 
continual stability. In contrast, the colonic inner mucus layer is effectively devoid of 
bacteria [35]. The small intestine does not have these two distinct layers, and instead 
relies on antimicrobial peptides / receptors such as RegIIIɣ and TLRs to minimise 
bacterial penetration of the mucus layer [22].  
An alternative mechanism explaining the interaction between the microbiome and 
immune system is through the development of antigen-presenting cells (APCs) such 
as dendritic cells and macrophages. Gastrointestinal dysbiosis has been shown to 
reduce infiltrating mature APCs [36]. Additionally, commensal bacteria can regulate 
dendritic cell activity. When investigating the role of the microbiome in APC 
development, it was found there were less gastrointestinal, but not systemic, 
dendritic cells in germ-free animals, and subsequent mono-colonisation of the 
gastrointestinal tract with E. coli caused gastrointestinal dendritic cell recruitment [37, 
38]. Additionally, microbe-derived adenosine triphosphate has been shown to 
stimulate CD70 and CX3CR1 expressing dendritic cells, which can then go on to 
induce differentiation of Th17 cells [39].  
The NLRP6 inflammasome is key in orchestrating the colonic host-microbiome 
interface [40], and is important in production of pro-inflammatory IL-18. Mice deficient 
in NLRP6 have been shown to be more susceptible to enteric infection [40], have an 
altered microbial biogeography and to have a dysbiotic bacterial profile more likely to 
cause colitis-like symptoms [41]. A recent paper has shown microbiome-modulated 
metabolites are able to regulate the NLRP6 inflammasome and subsequent IL-18 
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production [42]. These microbial metabolic products are also known to regulate the 
role of colonic regulatory T cell homeostasis among a raft of other effects [43]. 
The gut microbiome in CIGT 
The gut microbiome plays a variety of roles in the development of CIGT. One study 
showed that compared to germ-free mice, conventional mice treated with the same 
dose of irinotecan had more lesions within the jejunal intestinal epithelium and higher 
gastrointestinal permeability [44]. This was also reflected in another study, which 
showed that diarrhoea was more common in conventional mice compared to germ-
free mice, which also had a lowered intestinal damage score [45]. Rigby et al. [46] 
also showed the role of gastrointestinal bacteria in mediating doxorubicin-induced 
gastrointestinal damage by showing that germ-free mice did not display the changes 
in crypt depth and proliferative cell numbers that conventional mice treated with 
doxorubicin showed. Closely linked are the inflammatory pathways that are markedly 
upregulated in all cases of CIGT. It is now known that microbiome-host interactions 
modulate inflammatory cytokine production capacity [26]. Dysbioses of gut microbes 
are often linked to aberrant immune responses, often complemented by abnormal 
production of inflammatory cytokines. Additionally, commensal bacteria have 
protective effects on the integrity of the gastrointestinal mucosal barrier, including 
interactions with tight junctions and regulation of mucous layer [47].  
Research in pre-clinical models conducted over the past decade has shown a variety 
of changes to microbiome composition and diversity in the gastrointestinal tract due 
to chemotherapy treatment. There are some limitations to using pre-clinical 
microbiome models with 85% of bacterial sequences seen in a mouse representing 
genera not detected in humans [48]. However, there is also significant similarity in 
the distal gut microbiome between human and mice at a divisional level, and both 
have the same two most abundant bacterial divisions (Firmicutes and 
Bacteroidetes). Therefore pre-clinical models are often routinely used in this field.  
Pre-clinical studies show a decrease in commensal species following chemotherapy, 
which causes reduced protective effects and decreased resistance to pathogenic 
colonisation (table 1). This increase in pathogenic species also corresponds to an 
increase in gram negative species, which release LPS that is known to initiate the 
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inflammatory pathways involved in CIGT development [27]. These pre-clinical 
studies generally show decreases in Lactobacillus and Bifidobacterium and 
increases in Escherichia coli (E. coli) and Staphylococcus [49]. However, many of 
these studies used polymerase chain reaction (PCR) or microbial culture techniques 
to delineate species and changes. While these methods were standard at the time, 
with more sophisticated pyrosequencing techniques now the norm, these results 
may have limited reproducibility.  
A small number of clinical studies have also been conducted with patients 
undergoing chemotherapy, often replicating what has been shown in pre-clinical 
studies (table 1). However, due to a focus on clinical outcomes (e.g. diarrhoea 
severity), these studies have failed to conclusively link pre-treatment to post-
treatment microbiome composition. Results overall have included a decrease in total 
bacteria numbers and diversity [50, 51]. At a species specific level, findings have 
shown increases in Bacteriodetes, Clostridium cluster IV and E. coli [51, 52] and 
decreases in Lactobacillus, Bifidobacterium and Clostridium cluster XIV [52, 53].  
Attempts to ameliorate chemotherapy-induced changes to the microbiome profile 
have been variably successful in lowering damage severity. Administration of 
probiotics in pre-clinical models have attenuated gastrointestinal damage from 
chemotherapy by preventing apoptosis, reducing barrier disruption and promoting 
crypt survival (table 2) [54, 55]. However there have been inconsistencies, with level 
of diarrhoea reduction varying due to probiotic strains, dosing and treatment plan. 
For example in pre-clinical studies using Streptococcus thermophiles, one study 
showed promising results, with non-tumour bearing rats treated with methotrexate 
having attenuation of gastrointestinal damage [56], while another study utilising the 
same probiotic and chemotherapeutic in tumour bearing rats showed no benefit [57]. 
These studies additionally demonstrate a potential role of the tumour itself in 
regulating CIGT and gut microbiome changes, however further research is required 
to more fully understand this.  
Multiple clinical trials have used probiotics in patients undertaking chemotherapy, 
with Lactobacillus species have been a particular focus (table 2). For example, 
Osterlund et al. [58] showed that Lactobacillus supplementation led to less severe 
diarrhoea, less abdominal discomfort and fewer dose reductions after 5-fluorouracil 
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(5-FU) treatment for colorectal cancer. Subsequently, the Multinational Association 
for Supportive Care in Cancer (MASCC) released new clinical guidelines in 2014 
suggesting the use of “probiotic agents containing Lactobacillus species for the 
prevention of chemotherapy and radiation-induced diarrhoea in patients with a pelvic 
malignancy” [1].  Despite this, a recent meta-analysis found insufficient current 
evidence to support widespread implementation of probiotics after chemotherapy 
[59].   
Clinical trials have also investigated the impact of the antibiotic neomycin in 
combination with irinotecan, and results have shown less diarrhoea [60, 61]. 
However, a larger study conducted by de Jong et al. [62] did not find a substantial 
role for neomycin in reducing diarrhoea severity. Following inadequate / conflicting 
evidence, a 2013 systematic review was conducted and concluded that no clinical 
guideline for the use of neomycin was possible [63]. Another study administering 
antibiotics showed compromised anti-tumour efficacy of chemotherapy and an 
increase in potentially pathogenic bacteria [64]. These results may suggest that the 
removal of the entire microbiome with broad spectrum antibiotics does more harm 




Gastrointestinal toxicity, the microbiome and the innate immune system 
Modifications to both immune function and bacterial profile may influence severity of 
gastrointestinal injury following chemotherapy [75]. This could possibly occur via an 
altered capacity to mount an immune response. For example, commensal bacteria 
are able to induce CD4+ T cell differentiation. Specifically, Bacteroides fragilis can 
induce the development of a systemic Th1 response through polysaccharide A 
molecules [76]. It has been well established that Bacteroides genus levels are 
decreased by chemotherapy in both pre-clinical and clinical models [49, 64, 65]. This 
therefore leads to a potential decreased ability to mount a Th1 response after 
chemotherapy, which may affect the severity of gastrointestinal injury.  
The TIMER (translocation, immunomodulation, metabolism, enzymatic degradation, 
reduced diversity) model was recently proposed by Alexander et al. [9] to show the 
various ways the gut microbiome can influence chemotherapy efficacy and toxicity. It 
is possible that each part of this model is reliant on the microbiome’s interaction with 
the innate immune system, and thus the gut microbiome and innate immune system 
henceforth should be investigated together as much as practicable.  
There are a variety of ways this interaction could be studied in future. Currently, 
much CIGT research is undertaken in animals or relatively rudimentary cell cultures. 
Additionally, there are limitations to using animal pre-clinical models for microbiome 
models, with many strains present in the mouse microbiome not present in humans 
as discussed previously [48]. Reproducible and scientifically robust in vitro and ex 
vivo models are therefore needed to effectively study the microbiome in intestinal 
models. This may include using human tissue samples or stem cells to grow 
organoids, or the development of gut-on-a-chip technology to incorporate 
microbiome changes [77]. Additionally, recent trials of ingestible electronic capsules 
have showed the ability to sense gases produced by the microbiome in the 
gastrointestinal tract [78]. This may represent a real-time method of monitoring gut 
microbiome changes that could be paired with other analyses.  
Future opportunities for risk prediction and modification 
A personalised approach could soon be taken to manage CIGT, where a patient’s 
individual risk of toxicity could be managed early in their treatment plan. This 
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approach is supported by observations relating genetic testing on DNA extracted 
from saliva to severe CIGT, in which key immunogenetic factors relating to the TNF-
a and TLR2 have been correlated with more severe toxicity [79]. Whether the 
patient’s gut microbiome profile pre-cancer treatment could also predict toxicity 
severity is largely unknown, particularly in the setting of chemotherapy-induced 
damage. However, this idea was first postulated by Touchefeu et al. [50], and more 
recently by Wardill and Tissing [75]. Use of the microbiome as a predictive marker is 
gaining support in a variety of fields, including recent prediction of chemotherapy-
related bloodstream infection [80]. Studies may employ methods such as machine 
learning or metabolomics techniques to create an algorithm or predictive model in 
which a patient’s microbiome profile can be input to test risk of disease [80].  
There is some initial evidence that such an idea could also prove true in relation to 
other cancer treatment-induced toxicities (table 3), although as yet no study has 
investigated this following chemotherapy. One study of patients undergoing pelvic 
radiotherapy [81] found that patients who went on to develop diarrhoea had lower 
bacterial diversity and a higher Firmicutes / Bacteroidetes ratio. A study of patients 
suffering from oral mucositis after radiotherapy for head and neck cancers was also 
able to build a predictive model for the aggravation of oral mucositis (similar to CIGT 
in the oral cavity) [11]. Only one study has identified a protective phenotype of the 
gut microbiome for gastrointestinal toxicity [10]. This study measured development of 
checkpoint blockade-induced colitis in melanoma patients receiving the 
immunomodulatory therapy ipilimumab. Using 16S rRNA pyrosequencing 
techniques, it was shown that an increased representation of bacteria in the 
Bacteroidetes phylum before treatment was associated with resistance to 
development of colitis.  
Finally, one study [82] did not use a bacterial sequencing approach, but rather used 
the relatively novel method of an electronic nose and the Field Asymmetric Ion 
Mobility Spectrometry method, to analyse stool samples. Gases and other metabolic 
by-products of microbiome fermentation emitted from the samples were analysed. 
The patient pre-radiotherapy samples were successfully separated, using principal 
component analysis and linear discriminant analysis, into those who suffered from 
gastrointestinal toxicity and those who did not. This method represents a translatable 
14 
 
clinical test, where pre-treatment samples could be analysed, and future cancer 
treatment and supportive care measures adapted to suit.  
This emergent data on the role of the microbiome and the immune system in 
determining severity of cancer treatment-induced toxicities represents an additional 
opportunity to personalise cancer treatment, and allow the identification of patients at 
risk of severe symptoms. Alexander et al. [9] summarised evidence of being able to 
adapt the microbiome profile of the gastrointestinal tract using an enzyme inhibitor 
such as a β-glucuronidase inhibitor [83], changes in diet [84] or probiotics [55]. Of 
these, diet modification has been shown to be one of the most consistent and 
predictable ways of remodelling the microbiome, able to induce rapid shifts in 
composition and subsequent function [85]. An enzyme inhibitor may be particularly 
useful for patients undergoing irinotecan treatment, as the enzyme β-glucuronidase 
is crucial in irinotecan toxicity. SN-38, the active form of irinotecan, is conjugated in 
the liver to a less toxic metabolite, SN-38G. When excreted to the gastrointestinal 
tract via bile, it is hydrolysed back to the toxic SN-38 form by microbe-derived β-
glucuronidase [61, 67]. As discussed above, probiotics have previously been used in 
CIGT studies, with mixed results (table 2). There is currently a renewed call for 
carefully planned studies with new types of probiotics to better understand the 
potential benefits they could play in modulating CIGT risk [86]. Also required is better 
characterisation of the microbial profiles associated with toxicities caused by different 
agents to properly identify and develop the ideal microbial protectant. Finally, the 
developing area of faecal microbiota transplants and even faecal capsules represent 
methods of directly modifying the gut microbiome yet to be investigated in this 
context.   
Conclusion 
Effective treatments or predictive strategies for gastrointestinal toxicity caused by 
chemotherapy are urgently required. This under-reported but common adverse event 
has a substantial effect on quality of life and economic burden. Understanding the 
effect the gut microbiome and the innate immune system has on CIGT is key to 
developing treatment and prevention strategies. This review has summarised the key 
interactions between the gut microbiome and the innate immune system, and how 
these interactions may adversely affect gastrointestinal toxicity following 
15 
 
chemotherapy. We have also drawn emphasis to new data suggesting that the 
bidirectional interaction between microbiome and immune system is distinct to each 
patient and how we may be able to predict high-risk patients, thereby adjusting 
supportive care measures to each person. It is hoped that through pragmatic and 
rigorous scientific investigation, effective CIGT treatment may be within reach. 
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